At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Oral Budesonide Suspension (MB-9) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension
In Brief
A Phase 2 clinical trial evaluating Oral Budesonide Suspension (MB-9) and Placebo for Eosinophilic Esophagitis (EoE). Completed, enrolled 93 participants across 23 sites.
Detailed Summary
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis (EoE)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartJul 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedJul 17, 2012
Enrollment StartJul 23, 2012
Primary CompletionOct 30, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.0 years ago
Interventions
Oral Budesonide Suspension (MB-9)drug
OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
Placebodrug